Skip to main content
Qihan Biotech — Engineering Life

Our science

Technology platforms

Qihan develops technologies for multiplex genome editing, hypoimmune cell design and precision in vivo delivery.

Compare the platformsView pipeline
Conceptual rendering of a DNA double helix, an immune cell, and a delivery particle in one scene

Three roles in cell therapy development

Qihan is developing therapies made from donor cells and approaches that aim to create therapeutic cells inside the body.

  • Conceptual rendering of a DNA double helix

    HELIX®

    High-throughput genome editing

    Our foundational platform edits multiple genes in a single step to support the development of cell therapies.

    Explore HELIX®
  • Conceptual rendering of an immune cell

    QUIET®

    Hypoimmune cell design

    Built on HELIX®, QUIET® develops cell therapies with lower immunogenicity to address rejection of donor cells.

    Explore QUIET®
  • Conceptual rendering of a delivery particle beside a cell membrane

    INTACT®

    Precision in vivo delivery

    INTACT® develops delivery systems that direct therapeutic payloads to their intended cells inside the body.

    Explore INTACT®

How the platforms fit

HELIX® + QUIET®

Ex vivo allogeneic CAR-T

Donor-derived cells are engineered outside the body. HELIX® makes multiple edits possible, and QUIET® applies this editing capability to designs intended to reduce immune rejection.

View investigational candidate QT-019B

INTACT®

In vivo CAR-T

In vivo CAR-T aims to create therapeutic cells inside the body. INTACT® researches ways to guide delivery to the intended cells, a central challenge for this approach.

Explore the in vivo CAR-T pipeline

Research and collaboration